Antengene Corporation Limited
德琪醫藥有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6996)

POSITIVE PROFIT ALERT

This announcement is made by Antengene Corporation Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") is pleased to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on the preliminary review of the Group's unaudited consolidated management accounts for the six months ended June 30, 2026 (the "**Period**") and the information currently available to the Board, the Group is expected to record (i) a revenue in the range of RMB490.0 million to RMB536.0 million for the Period, as compared to a revenue of approximately RMB53.2 million for the six months ended June 30, 2025 (the "**Corresponding Period**"); and (ii) a profit in the range of RMB195.0 million to RMB238.0 million for the Period, as compared to a loss of approximately RMB76.4 million for the Corresponding Period. The anticipated increase in revenue and turnaround from loss to profit during the Period were mainly attributable to:

– the out-licensing and collaboration arrangement for ATG-201 (CD19×CD3) entered into with UCB, effective from March 2026, which constituted the primary revenue driver for the Period. As previously disclosed in the announcement of the Group dated July 13, 2026, the Group has received the upfront payment of USD60 million from UCB; and

– the exclusive out-licensing and collaboration agreement for ATG-106 (CDH6×CD3) entered into with K2 Therapeutics, effective from June 2026, which generated additional revenue during the Period.

As at the date of this announcement, the Company is still in the process of finalizing the interim results of the Group for the Period. The information contained in this announcement is only a preliminary assessment by the Board based on the unaudited consolidated management accounts of the Group for the Period currently available, which have not been reviewed by the audit committee of the Company, or reviewed or audited by the auditors of the Company.

The actual results of the Group for the Period is expected to be published by the end of August 2026. The above figures are provided for Shareholders' and investors' reference only.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By the order of the Board
Antengene Corporation Limited
Dr. Jay Mei
Chairman

Hong Kong, July 28, 2026

As at the date of this announcement, the Board comprises Dr. Jay Mei and Mr. Donald Andrew Lung as executive Directors; and Ms. Jing Qian, Mr. Sheng Tang and Dr. Rafael Fonseca as independent non-executive Directors.